Seoul: SK Biopharmaceuticals Co. (SK Biopharm), a biopharmaceutical subsidiary of SK Group, announced on Friday a net profit of 253.3 billion won (US$172 million) for the year 2025, reflecting an 11.6 percent increase from the previous year.
According to Yonhap News Agency, the company revealed in a regulatory filing that its operating profit for the year stood at 203.9 billion won, a significant rise from 96.3 billion won reported in the previous year. The annual sales also experienced a notable increase of 29.1 percent, reaching 706.7 billion won.